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Context: The Endocrine Society, and a growing number of other organizations, have adopted the
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to de-
velop clinical practice guidelines and grade the strength of recommendations and the quality of
the evidence. Despite the use of GRADE in several of The Endocrine Society’s clinical practice
guidelines, endocrinologists have not had access to a context-specific discussion of this system and
its merits.
Evidence Acquisition: The authors are involved in the development of the GRADE standard and its
application to The Endocrine Society clinical practice guidelines. Examples were extracted from
these guidelines to illustrate how this grading system enhances the quality of practice guidelines.
Evidence Synthesis: We summarized and described the components of the GRADE system, and
discussed the features of GRADE that help bring clarity and consistency to guideline documents,
making them more helpful to practicing clinicians and their patients with endocrine disorders.
Conclusions: GRADE describes the quality of the evidence using four levels: very low, low, mod-
erate, and high quality. Recommendations can be either strong (“we recommend”) or weak (“we
suggest”), and this strength reflects the confidence that guideline panel members have that pa-
tients who receive recommended care will be better off. The separation of the quality of the
evidence from the strength of the recommendation recognizes the role that values and prefer-
ences, as well as clinical and social circumstances, play in formulating practice recommendations.
(J Clin Endocrinol Metab 93: 666–673, 2008)
Professional organizations, such as The Endocrine Societyand its sister societies, have set out to develop clinical prac-
tice guidelines to provide helpful recommendations to practicing
clinicians, to improve quality of care, and to enhance patient
outcomes. By producing guidelines, these organizations seek to
assert their academic and practice leadership in areas of primary
concern. Given the policy and legal implications of guidelines,
state-of-the-art guideline developers follow rigorous and trans-
parent procedures for formulating recommendations for or
against a particular diagnostic or therapeutic intervention.
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Guidelines are strengthened further if they involve panel mem-
bers without substantial conflicts of interest (i.e. members who
do not expect to benefit directly or indirectly, now or in the
future, personally or financially, from making a particular rec-
ommendation) and conduct their proceedingswithout for-profit
support.Key to their success is the expectation that clinicianswill
deliver better care for their patients if they follow guideline rec-
ommendations. Thus, clinicians need to find the recommenda-
tions both clear and helpful.
In this article we will discuss the processes involved in devel-
oping helpful and rigorous clinical practice guidelines in a man-
ner congruent with the approach The Endocrine Society has
adopted. We anticipate that this will assist endocrinologists and
other parties who are interested in critically appraising, imple-
menting, andenhancingTheEndocrine Society’s clinical practice
guidelines.
Developing Rigorous and Helpful Clinical
Practice Guidelines
Evidence-based medicine recognizes two principles (1). The first
is that there is a hierarchy of evidence such that one is more
confident about decisions based on evidence that offers greater
protection against bias and random error. The second principle
is that evidence alone is never sufficient to make clinical deci-
sions. In fact, evidence-based medicine stipulates that optimal
treatment decisions require integration of clinical knowledge
and research evidence with patient circumstances, including
their values and preferences. The rigorous application of these
principles to the development of clinical practice guidelines is a
relatively recent development.
Therefore, evidence-based guidelines are most helpful when
they provide recommendations that are clear, based on the best
available research evidence, and transparent in terms of report-
ing the quality of the evidence and the basis for determining the
strength of the recommendations. Often this includes explicitly
describing the pertinent values and preferences the guideline au-
thors bring to bear in developing the recommendations.
Forover adecade,most guideline groupshave recognized that
developing a summary categorization of the strength of the rec-
ommendations and the quality of the evidence supporting them,
processes sometimes called grading (of the recommendation
strength) and rating (of the evidence quality), helps clinicians
understand a practice guideline’s summary message. Multiple
systems in use produce different grading and rating categories,
and rely on different letters, numbers, symbols, and terms (2).
This can cause confusion while clarity is needed.
To address this concern, the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) working
group, comprised of expert methodologists and guideline devel-
opers from a variety of health care organizations, set out to: 1)
evaluate these different systems, 2) develop one recommended
grading system, and 3) disseminate this system throughout med-
ical communities and their literature. The challenge was great
because many systems were already in place, all systems have
limitations, and many organizations have spent significant re-
sources on developing their rating system (3). GRADE’s design
criteria included simplicity and applicability to a wide variety of
clinical recommendations that encompass the full spectrum of
patientmanagement decisions. TheGRADEworking group first
published their findings in 2004 (4).
Since that time, numerous organizations have adopted
GRADE as their guideline grading system. These organizations
include The Endocrine Society, World Health Organization,
American College of Chest Physicians, UpToDate, American
CollegeofPhysicians,AmericanThoracic Society,TheCochrane
Collaboration, European Respiratory Society, Agency for
Healthcare Research and Quality, and Society of Critical Care
Medicine (a complete list is available on the GRADE working
group web site) (5). An emerging consensus seems to be forming
around the adoption of GRADE. This would be a welcome pro-
gression because such widespread adoption will help maintain
clarity and consistency in guidelines across medical disciplines.
The Endocrine Society appraised the merits of the GRADE
system and decided in late 2004 to adopt it as the basis for its
clinical practice guidelines. The Endocrine Society was the first
North American organization to adopt GRADE and use it in its
Clinical Practice Guidelines program. Guidelines on the use of
testosterone in men (6), on the treatment and prevention of pe-
diatric obesity, and on the diagnosis and treatment of hirsutism
are examples of the application of the GRADE system to The
Endocrine Society guidelines. However, endocrinologists have
not had access to a context-specific discussion of this system as
it relates to guidelines in endocrinology. In the following sec-
tions, we will use endocrinology examples to illustrate how this
grading system helps improve the rigor and usefulness of clinical
practice guidelines.
The GRADE System
The GRADE system classifies recommendations into one of two
grades (strong or weak) and the quality of the evidence into one
of four categories (high, moderate, low, or very low). This offers
a simple and practical, yet methodologically rigorous, grading
system for The Endocrine Society’s Clinical Practice Guidelines
program.
To enhance further the interpretation and clarity of the recom-
mendations, guideline developers use the terms “we recommend”
to denote strong recommendations, whereas weak recommenda-
tions use the less definitive wording “we suggest.” Furthermore, a
strong recommendation receives a grade 1 classification, and a
weak recommendation receives a grade 2 classification. The sym-
bols chosen for the four levels of quality of evidence are:
(very low);  (low);  (moderate); and 
(high) quality. Table 1 provides an overviewof theGRADE system
and a closer look at the components of each of its recommendation
categories.
Strength of Recommendations
The strength of a recommendation reflects the degree of confi-
dence that the desirable effects of a recommendation outweigh
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the undesirable effects. Desirable effects can include beneficial
health outcomes, less burden, and cost savings. Undesirable ef-
fects can include harms,more burden, and expenses. Burdens are
the demands of adhering to a recommendation that patients or
caregivers (e.g. their family) may dislike, such as having to take
medication or the inconvenience of going to the doctor’s office.
Although the degree of confidence is a continuum, the GRADE
approach classifies recommendations for or against treatments
into two grades, strong and weak.
If guideline developers are confident that the desirable effects
of adherence to a recommendation outweigh the undesirable
effects, they will make a strong recommendationwithin the con-
TABLE 1. GRADE recommendations–a closer look
Rating of evidence
quality Clarity of risk/benefit
Description of supporting
evidence Implications
Strong recommendations
High quality evidence Benefits clearly outweigh harms
and burdens, or vice versa
Consistent evidence from well-
performed RCTs or exceptionally
strong evidence from unbiased
observational studiesa
Recommendation can apply to most
patients in most circumstances.
Further research is very unlikely to
change our confidence in the
estimate of effect.
Moderate quality
evidence
Benefits clearly outweigh harms
and burdens, or vice versa
Evidence from RCTs with
important limitations
(inconsistent results,
methodological flaws, indirect or
imprecise evidence), or unusually
strong evidence from unbiased
observational studies
Recommendation can apply to most
patients in most circumstances.
Further research (if performed) is
likely to have an impact on our
confidence in the estimate of effect
and may change the estimate.
Low quality evidence Benefits clearly outweigh harms
and burdens, or vice versa
Evidence for at least one critical
outcome from observational
studies, from RCTs with serious
flaws, or indirect evidence
Recommendation may change when
higher quality evidence becomes
available. Further research is very
likely to have an important impact
on our confidence in the estimate
of effect and is likely to change the
estimate.
Very low quality
evidence (very rarely
applicable)
Benefits clearly outweigh harms
and burdens, or vice versa
Evidence for at least one of the
critical outcomes from
unsystematic clinical
observations or very indirect
evidence
Recommendation may change when
higher quality evidence becomes
available; any estimate of effect,
for at least one critical outcome, is
very uncertain.
Weak recommendations
High quality evidence Benefits closely balanced with
harms and burdens
Consistent evidence from well-
performed RCTs or exceptionally
strong evidence from unbiased
observational studies
The best action may differ depending
on circumstances or patient or
societal values. Further research is
very unlikely to change our
confidence in the estimate of
effect.
Moderate quality
evidence
Benefits closely balanced with
harms and burdens
Evidence from RCTs with
important limitations
(inconsistent results,
methodological flaws, indirect or
imprecise evidence), or unusually
strong evidence from unbiased
observational studies
Alternative approaches likely to be
better for some patients under
some circumstances. Further
research (if performed) is likely to
have an important impact on our
confidence in the estimate of effect
and may change the estimate.
Low quality evidence Uncertainty in the estimates of
benefits, harms, and burdens;
benefits may be closely
balanced with harms and
burdens
Evidence for at least one critical
outcome from observational
studies, from RCTs with serious
flaws, or indirect evidence
Other alternatives may be equally
reasonable. Further research is very
likely to have an important impact
on our confidence in the estimate
of effect and is likely to change the
estimate.
Very low quality
evidence
Major uncertainty in the
estimates of benefits, harms,
and burdens; benefits may or
may not be balanced with
harms and burdens
Evidence for at least one critical
outcome from unsystematic
clinical observations or very
indirect evidence
Other alternatives may be equally
reasonable. Any estimate of effect,
for at least one critical outcome, is
very uncertain.
Modified from Schunemann et al. (22).
a Exceptionally strong evidence from unbiased observational studies includes: 1) evidence from studies that yield estimates of the treatment effect that are large and
consistent; 2) evidence in which all potential biases may be working to underestimate an apparent treatment effect, and therefore, the actual treatment effect is likely
to be larger than that suggested by the study data; and 3) evidence in which a dose-response gradient exists.
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text of a described intervention. Typically, this requires high or
moderate quality evidence on patient important outcomes. Ex-
ceptionally, panels can make strong recommendations based on
low tovery lowquality evidence.Thismayoccurwhen the values
and preferences guideline developers bring to bear are such that
when considering even low quality evidence, they are confident
that the benefits of an intervention outweigh the undesirable
outcomes (or vice versa). In these cases the panel can make a
strong recommendation for (or against) the intervention.
For example, consider the decision to administer aspirin or
acetaminophen to children with chicken pox. Observational
studies have noted an association between aspirin administra-
tion and Reye syndrome. Because aspirin and acetaminophen
are, in this context, similar in their analgesic and antipyretic
effects, guideline developers may make a strong recommenda-
tion for acetaminophen despite the low quality evidence sug-
gestingharm fromaspirin because theyplace a veryhigh valueon
avoiding potential life-threatening adverse effects.
A weak recommendation is one for which a guideline panel
concludes that the desirable effects of adherence to a recommen-
dation probably outweigh the undesirable effects, but the panel
is not confident. Thus, if guideline developers believe that ben-
efits and downsides are finely balanced, or appreciable uncer-
tainty exists about this balance, they offer a weak recommen-
dation. Thus, low or very low quality evidence usually leads to
weak recommendations because of uncertainty about the bal-
ance between risks and benefits. Guideline panels may offer
weak recommendations evenwhenhighquality evidence is avail-
able when that evidence clearly demonstrates that the benefits
and risks are closely balanced. For example, a guideline panel
may weakly recommend bisphosphonates in relatively low-risk
patients with osteopenia, in whom the burden and costs of mon-
itoring and treatment may or may not be worth the potential
reduction in the risk of fragility fractures documented in ran-
domized trials.
Table 2 summarizes the factors that influence the strength of
a recommendation, factors that broadly correspond to: 1) cer-
tainty about thebalancebetweenbenefitsvs. burdens andharms,
2) resource use, and 3) variation in values and preferences. Con-
sideration of this latter issue is key. Guideline panels will typi-
cally, either explicitly or implicitly, use their own preferences as
imperfect proxies of patient values. Alternatively, they could
consider the range of patients to whom the recommendation
applies, and their range of values and preferences. Ideally, they
will find a way to ensure that the recommendation is consistent
with the values and preferences ofmost patients.How to achieve
this goal remains a challenge; one approach includes involving
relevant patients as panel members or involving patient groups
able tominimize influences that could bias their judgments in the
assessment of values and preferences.
There are practical implications relating the strength of rec-
ommendation for or against a therapy with patient values and
TABLE 2. Factors in deciding on a strong or weak recommendation
Issue Endocrinology example
Methodological quality of the evidence supporting
estimates of desirable and undesirable outcomes
Many high quality RCTs consistently show a large reduction in cardiovascular risk
among patients with diabetes treated with statins; only unsystematic clinical
observations support the type of glucocorticoid preparation used in patients
with adrenal insufficiency.
Importance of the outcome that treatment prevents Use of testosterone therapy in young patients with severe hypogonadism to
improve their quality of life vs. use of testosterone in asymptomatic, healthy
elderly men with low testosterone levels to normalize these levels.
Magnitude of treatment effect When compared with conventional control, tight blood pressure control reduces
the risk of diabetes-related complications to a greater extent (RRR 24%) than
tight glycemic control (RRR 12%) in patients with type 2 diabetes.
Precision of the estimate of treatment effect The relative risk associated with calcitonin for the prevention of vertebral
fractures has a wider confidence interval than the relative risk associated with
bisphosphonates.
Risks associated with therapy Metformin reduces hemoglobin A1c with much lower risk of hypoglycemia than
sulfonylureas.
Burdens of therapy In patients with newly diagnosed type 2 diabetes, insulin therapy is associated
with a higher burden than taking metformin; optimal insulin use requires
regular glucose self-monitoring and deliberate food intake.
Risk for target event Elderly women with a personal history of a fragility fracture have a much higher
risk of another fragility fracture than otherwise healthy elderly women with
low bone density.
Resource use Teriparatide is a more expensive treatment, and, thus, implies greater resource
use, for secondary prevention of osteoporotic fractures than oral
bisphosphonates.
Varying values Most young, healthy persons with hyperparathyroidism may put a high value on
avoiding prolonged medical monitoring and risk of complications (kidney
stones, bone fractures) and a low value on surgical risk, and, thus, may prefer
to undergo parathyroidectomy; many elderly and frail patients may put a high
value on avoiding surgical risk and a low value in avoiding periodic monitoring,
and, thus, may refuse surgery.
From Guyatt et al. (3). RRR, Relative risk reduction.
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preferences. For instance, a strong recommendation implies that
virtually all patients, across the range of individual values found
in the population, will make the same treatment decision. Strong
recommendations allow clinicians to offer treatment with con-
fidence, commonly with limited to no consideration of alterna-
tive options. Weak recommendations imply that different pa-
tients, in different clinical contexts, with different values and
preferences,will likelymakedifferent choices. In the faceofweak
recommendations, clinicians will need to bemore deliberate and
judicious in explicitly incorporating evidence regarding themag-
nitude of benefits and risks along with patient circumstances,
values, andpreferences tomake thebest decision. Inotherwords,
with weak recommendations, the clinician will need to have a
more detailed and deliberate discussionwith the patient, review-
ing several reasonable options. This is particularly important
when clinicians and patients find their own values and prefer-
ences atoddswith those theguidelinepanel considered inmaking
its recommendations.
We do not know how individual clinicians can best achieve
the goal of incorporating patient values and preferences in fol-
lowing a weak recommendation, but some promising ap-
proaches exist. For example, some clinicians are using decision
aids. Decision aids are tools that help clinicians communicate to
patients the relevant evidence about the available options and
their relative merits in a quantitative form. Examples of these
tools can be found elsewhere (for examples, see http://kerunit.
e-bm.org). Randomized trials have shown that these tools can
improve the quality of decision making in many clinical settings
(7). Conversely, for strong recommendations, a decision aid
could be an inefficient use of time and other resources; although
it is plausible that having the patient participate in making treat-
ment choices may enhance adherence to therapy (8).
Quality of the Evidence
To determine the strength of the recommendations, the GRADE
system explicitly considers the quality of the best available evi-
dence identified through a comprehensive review of the litera-
ture. Study design and conduct are important determinants of
quality. Randomized controlled trials (RCTs) allow decision
makers to draw causal inferences linking interventions and out-
comes with protection against bias. Therefore, RCTs begin with
a “high” quality rating.
Because of possible limitations that fall into five categories
(Table 3), even RCTs may not provide high quality evidence.
First, there may be serious limitations in the design and conduct
of RCTs (including lack of concealment and blinding, and large
loss to follow-up), and these limitations would lead to a reduc-
tion in the quality of the evidence base (weakening the inference
decision makers can draw from these data) and in turn a reduc-
tion in the quality level. For example, to inform guideline devel-
opers about the efficacy of physical activity on pediatric obesity,
the authors reviewed the results of a metaanalysis of 20 relevant
RCTs (9).These trials hadno reported allocation concealment or
blinding and had significant loss to follow-up (29% of studies
reported greater than a 20% loss). Therefore, the guideline panel
downgraded the quality of the evidence.
Second, if the results of trials are highly variable, wewill have
less confidence in the estimates of efficacy, and the evidence will
have lower quality. For instance, RCTs of testosterone use in
adult men reveal an inconsistent effect on lumbar spine bone
mineral density and on libido (in trials that enrolled men with
low testosterone levels) (10). These findings lower the quality of
the evidence. However, in the first case, a planned subgroup
analysis revealed a significant and large interaction between the
route of administration and the treatment effect, explaining the
inconsistency, and increasing the confidence of the guideline de-
velopers about the effect of intramuscular testosterone on lum-
bar spine bone mineral density (Figs. 1 and 2) (10). Thus, guide-
line developers did not need to downgrade the quality rating for
this evidence because of inconsistency. In contrast, developers
downgraded the evidence linking testosterone use and libido be-
cause of unexplained and very large inconsistency (11).
Third, a reduction in quality will occur when evidence sup-
porting a recommendation is indirect. Indirectness may occur if:
the patients enrolled in relevant trials differ in important ways
from those under consideration by the guideline panel; the in-
tervention or the comparator intervention tested in the trials
differ in important ways (nature, dosing, duration) from those
under consideration; or the outcomes differ (typically investiga-
tors will have measured effects on a substitute or surrogate out-
come, rather than the patient-important outcome in which the
guideline panel is primarily interested).
For example, when considering the use of testosterone gel to
prevent fragility fractures in elderly hypogonadal men, evidence
from trials enrolling younger men show that intramuscular tes-
tosterone can increase bone mineral density (12, 13). Here, the
evidence informs the efficacy of a different testosterone formu-
lation on a different patient group on a surrogate outcome of no
importance, in and of itself, to patients (bone density rather than
fracture risk); no high-quality trials have answered the question
of direct relevance to the guideline developer. If a recommenda-
tion was made specific to the use of testosterone gel to prevent
fractures in elderly men, the quality of the evidence would be
downgraded based on indirectness with respect to the popula-
tion, intervention, and outcome. Furthermore, the guideline
panel interested in making recommendations about the use of
TABLE 3. Factors in deciding on confidence in estimates of
benefits, risks, burdens, and costs
Factors that may decrease the quality of evidence
Poor quality of planning and implementation of the available RCTs
suggesting high likelihood of bias
Inconsistency of results
Indirectness of evidence
Lack of precision; sparse evidence
Reporting bias (including publication bias)
Factors that may increase the quality of evidence based on
observational studies
Large magnitude of effect
All plausible confounding would reduce a demonstrated effect
Dose-response gradient
From Guyatt et al. (3).
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testosterone for osteoporosis will have to rely only on indirect
comparisons (i.e. trials of each agent against placebo but no
head-to-head trials) when considering the relative merits of tes-
tosterone vs. bisphosphonates, for instance.
Fourth, guideline developers should downgrade evidence
when few studies, involving few participants and, most impor-
tantly, documenting few outcomes, inform the tradeoffs of risks
andbenefits.As an example, ametaanalysis of the results of trials
evaluating the effects of testosterone on cardiovascular out-
comes suggests that testosterone does not have an effect on car-
diovascular events. However, this result is based on only six
trials, a total of 308 participants, and only 21 outcomes. Con-
sidering the confidence interval width, the pooled data are con-
sistent with both a 1-fold decrease and a 4-fold increase in the
odds of cardiac events in patients treated with testosterone (14).
This evidence carries great uncertainty, lowering the confidence
that the estimates are accurate.
Finally, guideline developers should have limited confidence
when reportingbiasmighthave affected theunderlying evidence.
Publicationbias, one formof reportingbias, occursbecause trials
that show no significant effect are less likely to be published, and
outcome reporting bias occurs when researchers selectively re-
port their findings depending on their significance. Clinical trial
registries may help reduce publication bias (15). Chan et al. (16)
found that reporting of trial outcomes is frequently incomplete,
biased, and inconsistent with the original trial protocols. Pro-
spective public registration of trial protocols could help diminish
this concern. Box 1 describes an example of reporting bias. Pub-
lication bias is more likely to take place in fields in which small
trials are the norm (e.g. many endocrinopathies) because large
trials are less likely to remain unpublished. Although difficult to
ascertain, reporting bias is prevalent, particularly when key pa-
tient-important outcomes are only reported in a few studies.
In contrast to RCTs, observational studies start with a “low”
(i.e. case-control studies, and cohort studies) or “very low” (i.e.
unsystematic clinical observations, case re-
ports and series) quality level but may be
upgraded in certain situations, e.g. when the
magnitude of the treatment effect is very
large (e.g. use of insulin to prevent morbid-
ity and mortality in patients with type 1 di-
abetes presenting in diabetic ketoacidosis;
useof glucocorticoids toprevent adrenal cri-
sis inpatientswithAddison’s disease).Thus,
it is very important in guidelines to specify
clearly the alternatives considered. Al-
though high quality evidence, as we have
seen, supports the use of glucocorticoids to
prevent adrenal crises in patients with Ad-
dison’s disease, low quality evidence sup-
ports the choice of a specific glucocorticoid
replacement regimen out of several in com-
mon use.
In addition, the quality level can increase
when all plausible confounders would re-
duce the magnitude of the treatment effect,
yet the effect remains sizeable. For example,
a systematic review showed higher mortality in for-profit hos-
pitals when compared with not-for-profit hospitals (17). This
result occurred despite the fact that for-profit hospitals usually
haveadditional resources available andgenerally admithealthier
patients, factors that should work in their favor. Considering
these confounders would increase the magnitude of benefit of
not-for-profit hospitals (3). Table 3 summarizes factors that in-
fluence the quality of evidence.
Values and Preferences
As mentioned previously, values and preferences are essential to
guidelines. The GRADE system offers insights into the role of
values and preferences when it disentangles the strength of rec-
ommendations from the quality of the evidence, and encourages
statements about the underlying values and preferences relevant
to the recommendations.
Consider the interpretation of guidelines in the case of an
individual patient. A guideline may weakly recommend (a “sug-
gestion,” using the terminology of The Endocrine Society Clin-
ical Practice Guidelines) that patients receive treatment with a
medication based on low quality evidence because there is un-
certainty about the tradeoffs between potential desirable and
undesirable effects. An individual patient may place a high value
on potential resolution of their symptoms and a low value on
avoidingpossible side effects, costs, and follow-upvisits and tests
while taking the medication. Such a patient may prefer to take
this medication, in keeping with the suggestion. Another patient
in similar circumstances may have different values, placing a
higher value on avoiding potential adverse effects, costs, and
burdens of medical treatment.
For example, when making a decision on treatment options
for the prevention of osteoporotic fractures, some experts may
formulate recommendations in favor of treatment with teripa-
Random-effects pooled SMD (95%)
-1 0 1 2
Favors Testosterone
Hall
Reid
Fairfield
Amory
Crawford
Snyder
Howell
Kenny
SMD (95% CI)
0.31 (-0.42, 1.03)
0.82 (0.07, 1.57)
0.67 (0.05, 1.29)
0.49 (-0.08, 1.07)
0.95 (0.15, 1.76)
-0.07 (-0.44, 0.31)
-0.18 (-0.84, 0.49)
-0.05 (-0.64, 0.54)
0.25 (0.04, 0.45)
FIG. 1. Inconsistent results. This displays random-effects metaanalysis results of eight trials of
testosterone on lumbar spine bone mineral density. I2 (a statistic that reflects the proportion of variation
between studies that is not due to chance, i.e. inconsistency) is 46%, which identifies substantial
inconsistency. Vertical line indicates no treatment effect; squares and horizontal lines indicate point
estimates and associated 95% confidence intervals (CIs) for each study. Diamonds indicate the random-
effects pooled standard mean difference (SMD) with the width representing its confidence interval (10).
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ratide for women at high fracture risk. One woman may share
values and preferences in keeping with this recommendation,
whereas another woman, in the same situation, may find the
route of administration (injection) or the cost of teriparatide
unacceptable and would thus prefer not to take the medication.
The use of the GRADE system, with its transparency, offers
patients and clinicians the opportunity to consider and make
different clinical decisions, including decisions to not use an in-
tervention that is weakly recommended (or to use one that the
guideline weakly recommends against).
The appendix (published as supplemental data on The En-
docrine Society’s Journals Online web site at http://jcem.
endojournals.org) offers illustrations from
The Endocrine Society Clinical Practice
Guidelines to highlight the issues presented
here.
Future Directions
GRADE does not answer all questions re-
lated to rigorous guidelinedevelopment, but
many areas, such as diagnostic recommen-
dations and consideration of resource allo-
cation, are in active development.We antic-
ipate updating the endocrine readership
when further guidance becomes available.
In regards to considering resource allo-
cation in guidelines, there are challenges
concerning the clarity, conflicts, validity,
and applicability of the evidence (e.g. cost-
effectiveness analyses), challenges in the in-
terpretationanduseof economic analyses to
formulate guidelines (without the guidance
of a health economist), and the impact of
such analyses when guidelines are intended for broad, or even
international, audiences. The American College of Chest Physi-
cianshas suggestedanapproach to this problem that is consistent
with GRADE (18). The GRADE working group is preparing
documents and a conference that will provide additional guid-
ance on this topic.
There is also uncertainty as to the ideal composition of the
guideline panel. Some favor broad representation, expanding
from the usual set of clinical experts to include patients and
healthofficials.However, howto selectpatients forparticipation
in guidelines (e.g. highly educated patients are likely to partici-
pate actively, but they may not share values with many other
patients), how to engage them into the process, and how to ac-
knowledge their contribution is the subject of evolving science
(19–21). The promise of being able to incorporate values and
preferences in guideline development through direct patient con-
sultation seems a fascinating prospect.
Conclusions
Guideline development processes that are adherent to the prin-
ciples of evidence-based medicine, such as the GRADE system,
offer clarity, transparency, consistency, and helpfulness for ac-
ademic and professional organizations seeking to provide their
clinicians with practice recommendations. Further experience in
the use of GRADE in endocrine guidelines and familiarity of the
users with this system could enhance evidence-based endocrine
practice.
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